Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Feb;43(2):775-783.
doi: 10.1007/s10072-021-05756-4. Epub 2021 Nov 17.

Parkinson's disease and COVID-19: a systematic review and meta-analysis

Reza Jalili Khoshnood  1 , Alireza Zali  1 , Arash Tafreshinejad  1 , Mahsa Ghajarzadeh  2   3 , Narges Ebrahimi  4 , Saeid Safari  5 , Omid Mirmosayyeb  6   7
Affiliations
Meta-Analysis

Parkinson's disease and COVID-19: a systematic review and meta-analysis

Reza Jalili Khoshnood et al. Neurol Sci. 2022 Feb.

Erratum in

Abstract

Background: Patients with Parkinson's disease (PD) are at higher risk of COVID-19 infection as most of them are at older age. The goal of this study is to update the pooled prevalence of COVID-19 infection in patients with PD.

Methods: Two researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and also gray literature including references of the included studies which were published before September 2021. We extracted data regarding the total number of participants, first author, publication year, the country of origin, mean age, number with COVID-19, symptoms, hospitalization, and death.

Results: We found 1693 articles by literature search; after deleting duplicates, 798 remained. Thirty articles remained for meta-analysis. The pooled prevalence of COVID-19 infection in PD cases was 5% (95%CI: 4-6%) (I2 = 98.1%, P < 0.001). The pooled prevalence of fever in cases with PD was 4% (95%CI: 2-6%) (I2 = 96%, P < 0.001). The pooled prevalence of cough in cases with PD was 3% (95%CI: 2-4%) (I2 = 95.9%, P < 0.001). The pooled prevalence of hospitalization in cases with COVID-19 infection was 49% (95%CI: 29-52%) (I2: 93.5%, P < 0.001). The pooled prevalence of mortality in COVID-19 cases was 12% (95%CI: 10-14%) (I2 = 97.6%, P < 0.001).

Conclusion: The results of this systematic review and meta-analysis show that the pooled prevalence of COVID-19 infection in PD cases is 5% besides hospitalization and mortality rates which are 49% and 12%.

Keywords: COVID-19; Parkinson’s disease; Prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram summarizing the selection of eligible studies
Fig. 2
Fig. 2
The pooled prevalence of COVID-19 infection in PD cases
Fig. 3
Fig. 3
The pooled prevalence of fever in cases with PD
Fig. 4
Fig. 4
The pooled prevalence of cough in cases with PD
Fig. 5
Fig. 5
The pooled prevalence of hospitalization in cases with COVID-19
Fig. 6
Fig. 6
The pooled prevalence of death in COVID-19 cases
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Moghadasi AN, Mirmosayyeb O, Barzegar M, Sahraian MA, Ghajarzadeh M. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci. 2021;42(8):3093–3099. doi: 10.1007/s10072-021-05373-1. - DOI - PMC - PubMed
    1. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449–1458. doi: 10.1002/jmv.26424. - DOI - PMC - PubMed
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China Jama. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585. - DOI - PMC - PubMed
    1. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–1590. doi: 10.1002/mds.25945. - DOI - PubMed
    1. Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, De la Cruz-Ku GA, Custodio N. Factors associated with COVID-19 in people with Parkinson’s disease: a systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3467–3477. doi: 10.1111/ene.14912. - DOI - PMC - PubMed